The Molecular Pathogenesis Study of Cataract

Cataract Clinical Trial

Official title:

The Molecular Pathogenesis Study of Cataract

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05682001
• Other study ID #: CMP
• Status: Recruiting
• Start date: January 1, 2022
• Est. completion date: December 30, 2025

Study information

• Verified date: January 2023
• Source: Eye & ENT Hospital of Fudan University
• Contact: Lei Cai, MD
• Phone: 13816956828
• Email: clyc0318[@]126.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To study the molecular pathogenesis of cataract and explore possible treatments，anterior lens capsules were collected from cataract patients

Description:

Anterior lens capsules were collected from the patients with DC and ARC, and transparent crystals of cadaveric eyes. M6A epitranscriptomic microarray was performed to investigate the altered m6A modifications and determine the differentially expressed mRNAs. The potential role of dysregulated m6A modification levels was predicted through Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses. Real-time polymerase chain reaction was performed to identify the dysregulated expression of RNA methyltransferases, demethylases, and readers.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: December 30, 2025
• Est. primary completion date: December 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• diabetic cataract

• underwent cataract surgery

Exclusion Criteria:

• Combined with other eye diseases

• underwent other eye surgery

Related Conditions & MeSH terms

• Cataract
• Pathogenesis

Locations

Country	Name	City	State
China	Eye & ENT Hospital of Fudan University	Shanghai	Shanghai

Sponsors (2)

Lead Sponsor	Collaborator
Eye & ENT Hospital of Fudan University	National Natural Science Foundation of China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	m6A modification of mRNAs	Epitranscriptomic microarray analysis reveals the differential m6A modification of mRNAs in DC samples	1 month
Primary	expression level of mRNAs	the m6A microarray analyses provide data for mRNA expression levels	1 month
Primary	levels of methylated mRNA	in vitro validation of the diverse expression levels of methylated mRNA	1 month
Primary	levels of RNA methyltransferase	in vitro validation of the diverse expression levels of RNA methyltransferase	1 month